- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06:30 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | 4 | SGX Company Announcements | ||
| 21.04. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 07.04. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 4 | SGX Company Announcements | ||
| 27.03. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 4 | SGX Company Announcements | ||
| BIOCON BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 12.02. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 07.02. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | - | SGX Company Announcements | ||
| 28.01. | S&P Global upgrades Biocon Biologics ratings | 5 | Times of India | ||
| 28.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| 15.01. | Biocon Raises Rs 4,150 Crore Via QIP, To Buy Viatris Stake In Biocon Biologics | 20 | The Free Press Journal | ||
| 14.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | - | SGX Company Announcements | ||
| 06.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 06.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::ACQUISITION OF BBL SHARES AND ALLOTMENT OF BL EQUITY SHARES | 1 | SGX Company Announcements | ||
| 06.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::OUTCOME OF BOARD MEETING OF BIOCON LIMITED | 2 | SGX Company Announcements | ||
| 23.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| 13.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 11.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 08.12.25 | Viatris sells Biocon Biologics stake for $815 million in cash and equity deal | 38 | Seeking Alpha | ||
| 06.12.25 | Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln | 897 | AFX News | NEW DELHI (dpa-AFX) - Viatris Inc. (VTRS) announced that it has entered into definitive agreements with Biocon Limited for the sale of its equity stake in Biocon Biologics Limited. Under the... ► Artikel lesen | |
| 06.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::ANALYST CALL INTIMATION SUBMITTED BY BIOCON LIMITED | 3 | SGX Company Announcements | ||
| 06.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 3 | SGX Company Announcements |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 29,035 | +1,84 % | Qiagen senkt Jahresprognose - Aktie unter Druck | VENLO/HILDEN (dpa-AFX) - Der Labordienstleister und Diagnostikanbieter Qiagen blickt pessimistischer auf das laufende Jahr. Wegen verschiedener US-Einflussfaktoren und der zunehmenden geopolitischen... ► Artikel lesen | |
| BIONTECH | 88,50 | +1,72 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| ERASCA | 10,470 | +15,31 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| EVOTEC | 5,240 | +4,70 % | Evotec-Finanzvorstand geht aus persönlichen Gründen - Neue Finanzchefin ab Mai | HAMBURG (dpa-AFX) - Der Pharmawirkstoffforscher und -entwickler Evotec hat ab kommenden Monat eine neue Finanzchefin. Der bisherige Finanzchef Paul Hitchin werde das Unternehmen zum 30. April 2026... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,910 | -0,68 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| SUMMIT THERAPEUTICS | 21,960 | +5,53 % | Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth | ||
| INHIBRX BIOSCIENCES | 131,30 | +4,99 % | Morning Market Movers: Axe Compute, Inhibrx Biosciences, Huachen AI Parking Management Technology, 1-800-FLOWERS.COM See Big Swings | OTTAWA (dpa-AFX) - At 9:00 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ABSCI | 5,135 | +9,02 % | H.C. Wainwright reiterates Absci stock rating on hair loss data | ||
| PRAXIS PRECISION MEDICINES | 325,00 | +0,73 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| RECURSION PHARMACEUTICALS | 3,565 | +7,70 % | Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform | NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 62,70 | +3,33 % | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 | ||
| ENLIVEN THERAPEUTICS | 41,430 | -2,22 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| OSR HOLDINGS | 0,802 | +72,71 % | OSR Holdings, Inc.: OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 | OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 BELLEVUE, WA / ACCESS Newswire / April 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 11,600 | -1,61 % | Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | ~1.35 million total VOQUEZNA prescriptions filled to date$58.3 million in Q1 net revenues, a 104% increase year-over-yearQ1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2... ► Artikel lesen | |
| VERADERMICS | 101,70 | -5,16 % | Veradermics (MANE) Reports Positive Phase 2/3 Results for Male Pattern Hair Loss Treatment VDPHL01 |
BIOCON BIOLOGICS GLOBAL PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 100,01 Euro und damit -0,22 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCON BIOLOGICS GLOBAL PLC finden Sie auf Wallstreet Online.